Liaoning Chengda (600739.SH) announced first-half results, with net profit of 1.62 billion yuan to mother, an increase of 125.77% over the previous year

According to the Zhitong Finance App, Liaoning Chengda (600739.SH) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 4.411 billion yuan, a year-on-year decrease of 13.56%. Achieved net profit attributable to shareholders of listed companies of 1.62 billion yuan, an increase of 125.77% over the previous year. Achieved net profit of 1,635 billion yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 129.63% over the previous year.

During the reporting period, Chengda Biotech achieved double growth in domestic and international sales of rabies vaccine for human use, but due to adjustments in value-added tax policies, the biomedical sector achieved operating income of 677 million yuan, a year-on-year decrease of 4.18%; due to factors such as falling operating income compounded by rising costs and expenses, it achieved net profit of 0.3 million yuan, a year-on-year decrease of 72.79%.